AU2020271836C1 - Condensed azines for EP300 or CBP modulation and indications therefor - Google Patents

Condensed azines for EP300 or CBP modulation and indications therefor

Info

Publication number
AU2020271836C1
AU2020271836C1 AU2020271836A AU2020271836A AU2020271836C1 AU 2020271836 C1 AU2020271836 C1 AU 2020271836C1 AU 2020271836 A AU2020271836 A AU 2020271836A AU 2020271836 A AU2020271836 A AU 2020271836A AU 2020271836 C1 AU2020271836 C1 AU 2020271836C1
Authority
AU
Australia
Prior art keywords
inhibitor
oct
disclosure relates
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020271836A
Other languages
English (en)
Other versions
AU2020271836B2 (en
AU2020271836A1 (en
Inventor
John BUELL
Zuojun GUO
Hiroaki Inagaki
Yongil JIN
Phuongly Pham
Songyuan Shi
Wayne Spevak
Jack Walleshauser
Guoxian Wu
Jeffrey Wu
Chao Zhang
Jiazhong Zhang
Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opna Bio SA
Original Assignee
Opna Bio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70476481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020271836(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opna Bio SA filed Critical Opna Bio SA
Publication of AU2020271836A1 publication Critical patent/AU2020271836A1/en
Assigned to Opna Immuno-Oncology, SA reassignment Opna Immuno-Oncology, SA Request for Assignment Assignors: PLEXXIKON INC.
Assigned to Opna Bio SA reassignment Opna Bio SA Amend patent request/document other than specification (104) Assignors: Opna Immuno-Oncology, SA
Application granted granted Critical
Publication of AU2020271836B2 publication Critical patent/AU2020271836B2/en
Priority to AU2026200663A priority Critical patent/AU2026200663A1/en
Publication of AU2020271836C1 publication Critical patent/AU2020271836C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020271836A 2019-04-09 2020-04-08 Condensed azines for EP300 or CBP modulation and indications therefor Active AU2020271836C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200663A AU2026200663A1 (en) 2019-04-09 2026-01-30 Condensed azines for EP300 or CBP modulation and indications therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831622P 2019-04-09 2019-04-09
US62/831,622 2019-04-09
PCT/US2020/027282 WO2020210366A1 (en) 2019-04-09 2020-04-08 Condensed azines for ep300 or cbp modulation and indications therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200663A Division AU2026200663A1 (en) 2019-04-09 2026-01-30 Condensed azines for EP300 or CBP modulation and indications therefor

Publications (3)

Publication Number Publication Date
AU2020271836A1 AU2020271836A1 (en) 2021-10-28
AU2020271836B2 AU2020271836B2 (en) 2025-11-13
AU2020271836C1 true AU2020271836C1 (en) 2026-05-21

Family

ID=70476481

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020271836A Active AU2020271836C1 (en) 2019-04-09 2020-04-08 Condensed azines for EP300 or CBP modulation and indications therefor
AU2026200663A Pending AU2026200663A1 (en) 2019-04-09 2026-01-30 Condensed azines for EP300 or CBP modulation and indications therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200663A Pending AU2026200663A1 (en) 2019-04-09 2026-01-30 Condensed azines for EP300 or CBP modulation and indications therefor

Country Status (13)

Country Link
US (1) US11446287B2 (cg-RX-API-DMAC10.html)
EP (1) EP3953351A1 (cg-RX-API-DMAC10.html)
JP (1) JP7636646B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220018475A (cg-RX-API-DMAC10.html)
CN (1) CN113710668B (cg-RX-API-DMAC10.html)
AU (2) AU2020271836C1 (cg-RX-API-DMAC10.html)
BR (1) BR112021019957A2 (cg-RX-API-DMAC10.html)
CO (1) CO2021014306A2 (cg-RX-API-DMAC10.html)
IL (1) IL286992A (cg-RX-API-DMAC10.html)
MX (1) MX2021012278A (cg-RX-API-DMAC10.html)
SG (1) SG11202110714VA (cg-RX-API-DMAC10.html)
TW (1) TW202104221A (cg-RX-API-DMAC10.html)
WO (1) WO2020210366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
JP7636646B2 (ja) 2019-04-09 2025-02-27 オプナ バイオ ソシエテ アノニム Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
JP7842698B2 (ja) 2020-04-23 2026-04-08 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
AU2021327375A1 (en) 2020-08-21 2023-03-16 Opna Bio SA Combinational drug anticancer therapies
CN113880063B (zh) * 2021-09-28 2023-05-02 广东光华科技股份有限公司 废旧磷酸铁锂提锂后磷铁渣的除铝方法及电池级磷酸铁的制备方法
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054941A1 (en) * 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
WO2013075785A1 (de) * 2011-11-22 2013-05-30 Merck Patent Gmbh 3-cyanaryl-1h-pyrrolo[2,3-b]pyridin-derivate
WO2014053568A1 (en) * 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
WO2014145051A1 (en) * 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
WO2017053243A1 (en) * 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2018175311A1 (en) * 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
EP0154734B1 (en) 1984-03-15 1990-08-29 Immunex Corporation Immediate ligand detection assay, a test kit and its formation
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
BRPI0412684A (pt) 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
NZ553267A (en) * 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
AR075812A1 (es) 2009-03-11 2011-04-27 Plexxikon Inc Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
CA2784393A1 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
EP2576578B1 (en) * 2010-06-01 2018-09-19 Glycom A/S Polymorphs of 2'-o-fucosyllactose and producing thereof
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012129338A1 (en) * 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
CA2836474A1 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EP2978757B1 (en) * 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Indolinone analogues as brd4 inhibitors
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
ES2933616T3 (es) * 2014-12-16 2023-02-10 Glycom As Separación de 2'-FL de un caldo de fermentación
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN112574196A (zh) 2015-05-06 2021-03-30 普莱希科公司 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成
SMT202000535T1 (it) 2015-05-06 2020-11-10 Plexxikon Inc Forme solide di composto modulante chinasi
BR112017025045A2 (pt) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
HUE050936T2 (hu) 2015-05-22 2021-01-28 Plexxikon Inc Heterociklusos vegyületek szintézise
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
BR112019028235B1 (pt) 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
JP7636646B2 (ja) 2019-04-09 2025-02-27 オプナ バイオ ソシエテ アノニム Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
WO2021113625A1 (en) 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
TW202204354A (zh) 2020-04-02 2022-02-01 美商普雷辛肯公司 用於ｃｓｋ調節之化合物及方法以及其說明

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054941A1 (en) * 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
WO2013075785A1 (de) * 2011-11-22 2013-05-30 Merck Patent Gmbh 3-cyanaryl-1h-pyrrolo[2,3-b]pyridin-derivate
WO2014053568A1 (en) * 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
WO2014145051A1 (en) * 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
WO2017053243A1 (en) * 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2018175311A1 (en) * 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANU J. AIRAKSINEN ET AL: "Radiosynthesis and evaluation of new [alpha]1-adrenoceptor antagonists as PET radioligands for brain imaging", NUCLEAR MEDICINE AND BIOLOGY., vol. 40, no. 6, 1 August 2013 (2013-08-01), US, pages 747 - 754 *
JØRGENSEN MORTEN ET AL: "Discovery of novel [alpha]1-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 1, 15 November 2012, pages 196 - 204 *

Also Published As

Publication number Publication date
CA3136224A1 (en) 2020-10-15
IL286992A (en) 2021-12-01
JP7636646B2 (ja) 2025-02-27
KR20220018475A (ko) 2022-02-15
AU2020271836B2 (en) 2025-11-13
CN113710668A (zh) 2021-11-26
AU2026200663A1 (en) 2026-02-19
AU2020271836A1 (en) 2021-10-28
US11446287B2 (en) 2022-09-20
SG11202110714VA (en) 2021-10-28
TW202104221A (zh) 2021-02-01
CO2021014306A2 (es) 2021-11-19
BR112021019957A2 (pt) 2021-12-07
US20210315872A1 (en) 2021-10-14
WO2020210366A1 (en) 2020-10-15
CN113710668B (zh) 2025-01-07
JP2022527562A (ja) 2022-06-02
MX2021012278A (es) 2021-11-12
EP3953351A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
AU2020271836B2 (en) Condensed azines for EP300 or CBP modulation and indications therefor
AU2017395023B2 (en) Compounds and methods for CDK8 modulation and indications therefor
CA2961356C (en) Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto
WO2022061251A1 (en) Compounds and methods for kras modulation and indications therefor
CN105308036A (zh) 用于激酶调节的化合物和方法及其适应症
JP2016505596A (ja) Ｐｒｍｔ５阻害剤およびその使用
CA2931249A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
WO2015087151A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
WO2021113625A1 (en) Compounds and methods for cd73 modulation and indications therefor
EP4139296B1 (en) Compounds and methods for cd73 modulation and indications therefor
EA028035B1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
JP2024517473A (ja) Ｙａｐ／ｔｅａｄの調節のための化合物及び方法ならびにそれらの適用
TW202122382A (zh) 乙內醯脲衍生物
WO2021202900A1 (en) 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
JP2025503945A (ja) Ｙａｐ／ｔｅａｄ調節およびそれらの適応症のための化合物および方法
JP7688242B1 (ja) ３－フェニルプロピルアミン誘導体
JP2025525947A (ja) Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物
WO2024159079A1 (en) Compounds and methods for yap/tead modulation and indications therefor
EP4654972A1 (en) Compounds and methods for yap/tead modulation and indications therefor
HK40059454A (en) Condensed azines for ep300 or cbp modulation and indications therefor
CA3047580C (en) Compounds and methods for cdk8 modulation and indications therefor
CA3293795A1 (en) 3-phenylpropylamine derivative
EP4654969A1 (en) Compounds and methods for yap/tead modulation and indications therefor
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
HK40089725A (en) Compounds and methods for cd73 modulation and indications therefor

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OPNA IMMUNO-ONCOLOGY, SA

Free format text: FORMER APPLICANT(S): PLEXXIKON INC.

HB Alteration of name in register

Owner name: OPNA BIO SA

Free format text: FORMER NAME(S): OPNA IMMUNO-ONCOLOGY, SA

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 FEB 2026

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 FEB 2026

FGA Letters patent sealed or granted (standard patent)